XVIPF OTC
Xvivo Perfusion AB (publ)
1W: -12.8%
1M: -29.6%
3M: -24.8%
YTD: +5.3%
1Y: +14.4%
3Y: -4.0%
5Y: -31.8%
$21.80
-1.05 (-4.60%)
Weekly Expected Move ±9.7%
$18
$20
$22
$24
$26
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$810M
-1.5% ▼
5Y CAGR: +35.1%
Gross Profit
$532M
-13.7% ▼
5Y CAGR: +32.0%
Operating Income
$93M
+5.0% ▲
Net Income
$25M
-85.4% ▼
EPS (Diluted)
$0.80
-85.3% ▼
EBITDA
$153M
-47.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $258M | $415M | $598M | $822M | $810M |
| YoY Growth | +43.7% | +60.7% | +43.9% | +37.6% | -1.5% |
| Cost of Revenue | $70M | $118M | $152M | $206M | $278M |
| Gross Profit | $188M | $297M | $445M | $616M | $532M |
| Gross Margin | 72.9% | 71.5% | 74.5% | 75.0% | 65.7% |
| R&D Expenses | $54M | $69M | $136M | $148M | $100M |
| SG&A Expenses | $153M | $223M | $309M | $380M | $377M |
| Operating Expenses | $207M | $293M | $441M | $528M | $439M |
| Operating Income | -$18M | $6M | $4M | $88M | $93M |
| Operating Margin | -7.2% | 1.5% | 0.7% | 10.7% | 11.5% |
| Interest Expense | $276K | $605K | $1M | -$62M | $44M |
| Income Before Tax | $7M | $22M | $95M | $200M | $38M |
| Tax Expense | -$1M | $4M | $3M | $28M | $13M |
| Net Income | $8M | $18M | $92M | $172M | $25M |
| Net Margin | 3.2% | 4.4% | 15.4% | 20.9% | 3.1% |
| EPS (Diluted) | $0.28 | $0.62 | $3.07 | $5.44 | $0.80 |
| EBITDA | $39M | $39M | $81M | $289M | $153M |
| Shares Outstanding | 29M | 30M | 30M | 32M | 32M |